Zacras tablets, prescribed for the management of hypertension, comprise a dual active pharmaceutical ingredient formulation consisting of amlodipine and azilsartan. These two active principles function synergistically to regulate blood pressure through distinct mechanisms of action.
Amlodipine, a dihydropyridine calcium channel blocker, operates by selectively inhibiting L-type calcium channels primarily found in vascular smooth muscle cells. By doing so, amlodipine reduces the influx of calcium ions into these cells, leading to decreased intracellular calcium levels. This, in turn, results in vasodilation, primarily affecting peripheral blood vessels. Vasodilation leads to a decrease in vascular resistance, which in the context of hypertension, equates to a lowered systemic vascular resistance. Consequently, amlodipine effectively reduces systolic and diastolic blood pressure by promoting relaxation of the arterial walls and enhancing blood flow.
Azilsartan, on the other hand, belongs to the angiotensin II receptor blocker (ARB) class of medications. Azilsartan functions by antagonizing angiotensin II receptors, particularly the type 1 (AT1) receptor subtype. Angiotensin II is a potent vasoconstrictor hormone that plays a pivotal role in blood pressure regulation by causing constriction of blood vessels and promoting salt and water retention. By blocking the AT1 receptors, azilsartan interferes with the actions of angiotensin II, leading to vasodilation, decreased vascular resistance, and ultimately, a reduction in blood pressure.
The synergistic action of amlodipine and azilsartan in Zacras tablets combines the benefits of calcium channel blockade and angiotensin II receptor blockade, resulting in an effective reduction of both systolic and diastolic blood pressure. This comprehensive approach addresses hypertension from two distinct angles, enhancing its efficacy in controlling blood pressure levels.
Research studies have supported the safety and effectiveness of the azilsartan/amlodipine combination in Zacras tablets. Clinical trials have demonstrated a significant reduction in blood pressure with this medication regimen, with most patients achieving their target blood pressure goals. Furthermore, the incidence of adverse effects associated with Zacras tablets is notably low, making it a well-tolerated treatment option for individuals with hypertension.
Active principles:
azilsartan 20 mg,
amlodipine besilate 5 mg
Amount: 100 tablets
Maker: Takeda Pharmaceutical Co., Ltd., Tokyo, Japan
Indications: treatment of hypertension
Adults should take 1 tablet at a time, once a day.
Contraindications: do not use for the following patients:
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.
